The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...

In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...

Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair ...

The technology aims to significantly reduce waiting times by efficiently triaging patients with suspicious skin lesions. DERM (Deep Ensemble for Recognition of Malignancy), developed by Skin Analytics ...

This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk ...

Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test. Last reviewed: 16 April 2025 Next review: This guidance ...

Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health ...

Around 1,000 women per year with endometriosis could benefit from this new treatment that: Starts working more quickly than injectable alternatives Can be taken at home rather than at clinics Combines ...

Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over. Last reviewed: 26 February 2025 Next review: More evidence on ...

Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults. Last ...